FDA feedback supports planned trial and possible early approval for Black Diamond lung cancer drug
Stock Titan reports that feedback from the FDA supports a planned trial and a possible early approval for a lung cancer drug from Black Diamond.
“FDA feedback supports a planned trial and possible early approval for Black Diamond's lung cancer drug.”— Stock Titan
Feedback from the US Food and Drug Administration (FDA) supports a planned trial and a possible early approval for Black Diamond's lung cancer drug, according to a news item published by Stock Titan on 10 November 2026.
The item, as available, consists of a single headline statement. It does not name the drug, describe the planned trial's design or patient population, or say what form of early approval might be pursued.
It also gives no timelines, and no comment from Black Diamond or the FDA. LungDaily will update this report if further details are published.
